Sponsor Directory

AstraZeneca clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1904

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Hepatic Impairment, Hepatic Insufficiency, Healthy Subjects
Interventions: acalabrutinib; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Knoxville, Tennessee

Conditions: Solid Tumor
Interventions: Prexasertib, Olaparib; Drug
Lead sponsor: Geoffrey Shapiro, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: AZD9496 (Reference), AZD9496 Variant A, AZD9496 Variant B, AZD9496 Variant C, AZD9496 Variant D; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Triple Negative Breast Cancer
Interventions: Durvalumab, Radiation Therapy, Carboplatin, Paclitaxel; Drug · Radiation
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Solid Tumors
Interventions: Savolitinib, Midazolam; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Interventions: Epanova® (omega-3 carboxylic acids), corn oil control; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 13,078 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 229
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 183 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Ceralasertib, Olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Asthma
Interventions: Tezepelumab (APFS), Tezepelumab (AI); Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 16
States / cities: Hoover, Alabama • Gilbert, Arizona • Northridge, California + 12 more

Conditions: Heart Failure
Interventions: AZD4831, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 45 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Chicago, Illinois • Boston, Massachusetts

Conditions: Non Small Cell Lung Cancer
Interventions: Pharmacokinetic sampling - AZD9291, Rifampicin, AZD9291 tablet dosing, Pharmacokinetic sampling - rifampicin, Pharmacokinetic sampling - AZ5140 and AZ7550; Procedure · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 2
States / cities: Atlanta, Georgia • Detroit, Michigan

Conditions: Chronic Kidney Disease
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 4,304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 55
States / cities: Birmingham, Alabama • Hawaiian Gardens, California • Lomita, California + 46 more

Conditions: Dyslipidemia
Interventions: AZD8233 subcutaneous injection, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 7
States / cities: Chula Vista, California • Glendale, California • La Mesa, California + 4 more

About this AstraZeneca sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AstraZeneca is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AstraZeneca trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AstraZeneca clinical trials

Filter and sort this sponsor

Live official records

Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects

Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer

A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

Tezepelumab Home Use Study

Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.

Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia

About this AstraZeneca sponsor directory page